ProMIS Neurosciences Inc
TSX:PMN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ProMIS Neurosciences Inc
TSX:PMN
|
CA |
|
T
|
Tecnotree Oyj
OMXH:TEM1V
|
FI |
|
XANO Industri AB
STO:XANO B
|
SE |
|
N
|
N-Able Inc
NYSE:NABL
|
US |
|
OneStream Inc
NASDAQ:OS
|
US |
|
Bank of Baroda Ltd
NSE:BANKBARODA
|
IN |
|
Shriram City Union Finance Ltd
NSE:SHRIRAMCIT
|
IN |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
US |
|
PolyPid Ltd
NASDAQ:PYPD
|
IL |
ProMIS Neurosciences Inc
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
